envolizumab + sovalteinib

envolizumab + sovalteinib is a combination therapy being evaluated for the treatment of advanced or refractory bile duct cancer. Envolizumab (also known as envafolimab or KN035) is a humanized single-domain antibody (nanobody) fused to a human IgG1 Fc region that acts as a PD-L1 antagonist. It is notable for being the first PD-L1 inhibitor designed for subcutaneous administration. Sovalteinib (also known as catequentinib or AL3818) is an orally active, multi-targeted tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3), platelet-derived growth factor receptors (PDGFR alpha/beta), and c-Kit. The combination aims to synergize the immune-restoring effects of checkpoint inhibition with the anti-angiogenic and anti-proliferative effects of multi-kinase inhibition to improve outcomes in patients with biliary tract cancers who have failed prior systemic therapy. This regimen is currently being investigated in Phase II clinical trials sponsored by Zhejiang Cancer Hospital.

Brand names

Enweida

Other names

EnvafolimabCatequentinibSovaltinibEnvelizumabSoventinib